Serum HER-2 concentrations for monitoring women with breast cancer in a routine oncology setting

Clinical Chemistry and Laboratory Medicine

Volumn 47, Issue 9, 2009, Pages 1117-1123

  Sørensen, Patricia Diana ^a   Jakobsen, Erik Hugger ^a   Langkjer, Sven Tyge ^a   Bokmand, Susanne ^a   Østergaard, Birthe ^a   Olsen, Dorte Aalund ^a   Madsen, Jonna Skov ^a   Brandslund, Ivan ^a  

^a LILLEBAELT HOSPITAL   (Denmark)

Author keywords

Breast cancer; Breast tissue; Metastases; Progression; Recurrence; Regression; Serum human epidermal growth factor receptor 2 (HER 2)

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; LAPATINIB; NAVELBINE; PACLITAXEL; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGED; ARTICLE; ASSAY; BREAST CANCER; BREAST INVASIVE LOBULAR CARCINOMA; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURGERY; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATIONAL STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MONITORING; ONCOLOGY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SKIN METASTASIS; THERAPY EFFECT; TISSUE LEVEL;

ADULT; AGED; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; RECEPTOR, ERBB-2;

EID: 70349512809     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2009.241     Document Type: Article

References (17)

1. Olsen DA, Ostergaard B, Bokmand S, Wamberg PA, Jakobsen EH, Brandslund I. HER-2 protein concentrations in breast cancer cells increase before immunohistochemical and fluorescence in situ hybridization analysis turn positive. Clin Chem Lab Med 2007;45:177-182
2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182
3. Zabrecky JR, Lam T, McKenzie SJ, Carney W. The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3. J Biol Chem 1991;266:1716-1720
4. Carney WP, Leitzel K, Ali S, Neumann R, Lipton A. HER- 2/neu diagnostics in breast cancer. Breast Cancer Res 2007;9:207.
5. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216 (Pubitemid 30099779)
6. Gehan EA, Tefft MC. Will there be resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)? J Natl Cancer Inst 2000;92:179-181
7. Gerhardt W, Keller H. Evaluation of test data from clinical studies. I. Terminology, graphic interpretation, diagnostic strategies, and selection of sample groups. II. Critical review of the concepts of efficiency, receiver operated characteristics (ROC), and likelihood ratios. Scand J Clin Lab Invest Suppl 1986;181:1-74.
8. Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:1800-1808 (Pubitemid 34273269)
9. Kong S-Y, Nam BH, Lee KS, Kwon Y, Lee ES, Seong MW, et al. Predicting tissue HER2 status using serum HER2 levels in patients with metastatic breast cancer. Clin Chem 2006;52:1510-1515
10. Carney WP, Neumann R, Lipton A, Leitzel K, Ali S, Price CP. Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer. Clin Chem 2003;49:1579-1598
11. Kandl H, Seymour L, Bezwoda WR. Soluble c-erbB-2 fragment in serum correlates with disease stage and predicts for shortened survival in patients with earlystage and advanced breast cancer. Br J Cancer 1994;70: 739-742
12. Molina R, Jo J, Filella X, Zanon G, Pahisa J, Munoz M, et al. C-erbB-2 oncoprotein in the sera and tissue of patients with breast cancer. Utility in prognosis. Anticancer Res 1996;16:2295-2300
13. Gancberg D, Di LA, Cardoso F, Rouas G, Pedrocchi M, Paesmans M, et al. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 2002;13:1036-1043
14. Zidan J, Dashkovsky I, Stayerman C, Basher W, Cozacov C, Hadary A. Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer 2005;93:552-556
15. Luftner D, Luke C, Possinger K. Serum HER-2/neu in the management of breast cancer patients. Clin Biochem 2003;36:233-240
16. Ardavanis A, Kountourakis P, Kyriakou F, Malliou S, Mantzaris I, Garoufali A, et al. Trastuzumab plus paclitaxel or docetaxel in HER-2-negative/HER-2 ECD-positive anthracycline- and taxane-refractory advanced breast cancer. Oncologist 2008;13:361-369
17. Ali SM, Carney WP, Esteva FJ, Fornier M, Harris L, Kostler WJ, et al. Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer. Cancer 2008;113:1294-1301